Shots:
Samsung Bioepis & Teva have expanded their strategic partnership to advance up to ~6 biosimilar candidates, incl. SB41, a biosimilar version of Fasenra (benralizumab), & SB44, a biosimilar to Ilaris (canakinumab)
As per the deal, Samsung Bioepis will develop, manufacture & handle regulatory registration of the biosimilars, while Teva will lead commercialization in the…
